Pharmaceutical marketing

 Virpax Pharmaceuticals Announces Leadership Transition

Retrieved on: 
Friday, November 17, 2023
Biotechnology, Health, Finance, Other Health, Pharmaceutical, Surgery, Professional Services, Other Science, Practice Management, Medical Devices, Infectious Diseases, Hospitals, Science, Veterinary, CNS, Neurogenic inflammation, Silence Therapeutics, Meharry Medical College, Pharmaceutical marketing, Regulatory affairs, Therapy, Post-traumatic stress disorder, Quality assurance, Lincoln University, Commercial Operating System, Pain management, Patient, INSEAD, Merck, Medication, Clobazam, Nitrome, Sanofi, Trustee, Novartis, University, Harvard Medical School, Axovant Sciences, Tennessee State University, Champaign–Urbana metropolitan area, Central nervous system, Business, DSM-IV codes, International business, Pharmaceutical industry, Management, Analgesic, Schizophrenia, Biology, Neurophysiology, Lundbeck, Neuroscience, Droxidopa

Prior to Virpax, Mr. Bruce served as Vice President of sales for Danone Specialized Nutrition North America, Danone’s medical nutrition division.

Key Points: 
  • Prior to Virpax, Mr. Bruce served as Vice President of sales for Danone Specialized Nutrition North America, Danone’s medical nutrition division.
  • He has a BA from Lincoln University and a Master’s degree in Leadership from Georgetown University’s McDonough School of Business.
  • Aside from Virpax Pharmaceuticals, he also serves on the board of Advent Therapeutics Inc. and is a member of the Board of Trustees of Meharry Medical College.
  • I am proud of what we have accomplished together and confident that Virpax under Gerald and Eric’s leadership will remain on track to begin first-in-human trials in the coming year,” commented Mr. Mack.

Pharmaceutical Temperature-Controlled Packaging Market, 2028 - Pharma TCP Market Digitization to Cut Costs and Streamline Processes - ResearchAndMarkets.com

Retrieved on: 
Monday, September 4, 2023
Packaging, Pharmaceutical, Health, Manufacturing, Vaccine, PCM, Research report, Pfizer, Pharmaceutical marketing, Dry ice, TCP, COVID-19, Intelligence, Temperature, COVID, FedEx, Patent, Biophysical environment, Growth, ESG, Johnson & Johnson, PCM, Inc., Lithium, Medical device, Electric battery, Pharmaceutical industry, Retail, Moderna

Pharmaceutical Temperature-Controlled Packaging Market is projected to reach a value of $16.8 billion by 2028 from $10.6 billion in 2023, growing at a CAGR of 9.5%.

Key Points: 
  • Pharmaceutical Temperature-Controlled Packaging Market is projected to reach a value of $16.8 billion by 2028 from $10.6 billion in 2023, growing at a CAGR of 9.5%.
  • This research report incorporates an in-depth analysis of the global temperature-controlled packaging market, including market estimates and trends through 2028.
  • Major players, competitive intelligence, innovative technologies, market dynamics, sustainability in the cold chain, and market opportunities are discussed in detail.
  • Temperature-controlled packaging (TCP) is created and validated by strict requirements to maintain products within a particular temperature range for a predetermined amount of time.

EQS-News: Abivax appoints Michael Ferguson as Chief Commerical Officer

Retrieved on: 
Tuesday, April 18, 2023
Pharmaceutical marketing, Inflammatory Bowel Diseases, Therapy, Arena Pharmaceuticals, Marketing, IBD, Pennsylvania State University, East Coast of the United States, CCO, Ulcerative colitis, Euronext Paris, UC, Patient, M.B.A, Immune system, CEST, Inflammatory bowel disease, Pharmaceutical industry, Abivax, Gastroenterology

Therefore, Pierre Courteille will be focusing on business development activities and is appointed Chief Business Officer.

Key Points: 
  • Therefore, Pierre Courteille will be focusing on business development activities and is appointed Chief Business Officer.
  • Abivax is strengthening its expertise in the commercial and business development field to foster the evolution of the Company towards future commercialization of obefazimod.
  • Michael Ferguson brings over 22 years of experience in the biopharmaceutical industry, with an extensive track record in the field of Gastroenterology (GI) and Inflammatory Bowel Disease (IBD).
  • From a global marketing perspective, obefazimod’s convenient once-daily oral administration will be a big advantage for both patients and gastroenterologists.”

Reefer Container for Pharmaceutical Sector Global Market to Grow at 12.5% Annually Through 2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, October 14, 2022
HVAC, Pharmaceutical, Health, Manufacturing, Adoption, Assistant, Government, Transport, Growth, Royal commission, Strategic National Stockpile, Vaccine, Policy, CAGR, HHS, Personal protective equipment, Hapag-Lloyd, SNS, Bureau of Economic Analysis, Temperature, Pharmaceutical marketing, PPE, Economics, United States Department of Health and Human Services, Bureau, Office of the Assistant Secretary for Preparedness and Response, Fesco Transport Group, COVID-19, European Commission, Cardinal Health, Pharmaceutical industry

The "Reefer Container for Pharmaceutical Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Application Type and Container Size" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Reefer Container for Pharmaceutical Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Application Type and Container Size" report has been added to ResearchAndMarkets.com's offering.
  • The reefer container for pharmaceutical market is expected to reach US$ 6,391.8 million by 2028 from US$ 2,846.7 million in 2021.
  • The growth of the reefer container for pharmaceutical market in North America is primarily attributed to the increasing demand for refrigerated medicines, vaccines, and blood plasma along with the government policies encouraging international trade.
  • The growing initiatives from the European Commission for designing regulations and policies drive the growth of the reefer container for the pharmaceutical market in Europe.

EQS-News: Laxxon Medical: Granted U.S. Patent for the Sequential Release of Multiple Drugs Within Pharmaceutical Dosage Forms, Strengthening the Company’s Intellectual Property Position in Pharmaceutical Market

Retrieved on: 
Thursday, September 22, 2022
Medication, 3D, Pharmaceutical marketing, Administration, NEW, Health, Screen, USPTO, Technology, United States Patent and Trademark Office, Patent, DDS, API, Method, Pharmacokinetics, Medicine, NY, United States patent law, Pharmaceutical industry, Generic drug

Laxxon Medical: Granted U.S. Patent for the Sequential Release of Multiple Drugs Within Pharmaceutical Dosage Forms, Strengthening the Companys Intellectual Property Position in Pharmaceutical Market

Key Points: 
  • Laxxon Medical: Granted U.S. Patent for the Sequential Release of Multiple Drugs Within Pharmaceutical Dosage Forms, Strengthening the Companys Intellectual Property Position in Pharmaceutical Market
    The issuer is solely responsible for the content of this announcement.
  • "This patent is a great success for Laxxon's global IP strategy and will enhance our position within the competitive pharma market significantly."
  • The patent covers the sequential release of at least two active pharmaceutical ingredients (API) within a drug delivery system (DDS) through 3D printing.
  • Laxxon Medical holds the exclusive worldwide rights to the use and application of SPID-Technology for the development, manufacture, and commercialization of pharmaceutical dosage forms.

Pharmaceutical Clinical Trial Supply & Logistics Market Intelligence Report 2022 - Global Forecast to 2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, August 26, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Culture, USD, Pharmaceutical marketing, Industry, CAGR, Pharmaceutical industry

The "Clinical Trial Supply & Logistics for Pharmaceutical Market Intelligence Report - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Clinical Trial Supply & Logistics for Pharmaceutical Market Intelligence Report - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The Global Clinical Trial Supply & Logistics for Pharmaceutical Market is projected to reach USD 30.59 billion by 2027 from USD 19.60 billion in 2021, at a CAGR 7.69% during the forecast period.
  • The report on clinical trial supply & logistics for pharmaceutical identifies key attributes about the customer to define the potential market and identify different needs across the industry.
  • The Americas Clinical Trial Supply & Logistics for Pharmaceutical Market size was estimated at USD 7,698.04 million in 2021, is expected to reach USD 8,279.20 million in 2022, and is projected to grow at a CAGR of 7.65% to reach USD 11,983.99 million by 2027.

Mid-Size Pharmaceutical Market Report 2022: Increasing Prevalence of Chronic Disorders along with Increasing Product Approval and Launches Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 4, 2022
Health, Pharmaceutical, Prevalence, Urbanization, Pharmaceutical marketing, Tablet, Capsule, Conditional sentence, COVID-19, Obesity, Degenerative disease, Social behavior, CAGR, Diabetes, Cancer, Pain management, Ageing, R, Population, Pharmaceutical industry, Dietary supplement

The mid-size pharmaceutical market is expected to grow from US$ 6,51,349.9 million in 2021 to US$ 10,00,584.3 million by 2028.

Key Points: 
  • The mid-size pharmaceutical market is expected to grow from US$ 6,51,349.9 million in 2021 to US$ 10,00,584.3 million by 2028.
  • The increasing prevalence of chronic diseases and the rising number of products launches & approvals drive the market growth.
  • However, cutthroat competition among market players hampers the mid-size pharmaceutical market growth.
  • The increasing prevalence of chronic diseases, rapidly rising elderly population, and the surging number of products launches & approvals is expected to aid the mid-size pharmaceutical market growth.

Clinical Trial Supply & Logistics for Pharmaceutical Market Report 2022-2027: Increasing R&D Expenditure of Pharmaceutical and Biopharmaceutical Industry Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, July 25, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Investment, Market share analysis, Acquisition, Compound annual growth rate, Clinical trial, Extrapyramidal system, Gaps, Value, Decision-making, Use, Oncology, Pharmaceutical marketing, Weakness, Research, Medication, Strategic management, Customer support, USD, COVID-19, News, CAGR, Mergers and acquisitions, Lists of diseases, Collaborative partnership, Degenerative disease, Growth, Business Growth Fund, Pharmaceutical industry, Retail

This research report categorizes the Clinical Trial Supply & Logistics for Pharmaceutical to forecast the revenues and analyze the trends in each of the following sub-markets:

Key Points: 
  • This research report categorizes the Clinical Trial Supply & Logistics for Pharmaceutical to forecast the revenues and analyze the trends in each of the following sub-markets:
    Based on Phase, the market was studied across BA/BE Studies, Phase I, Phase II, Phase III, and Phase IV.
  • Based on Sector, the market was studied across Clinical Trial Logistics and Distributions, Clinical Trial Manufacturing Services, and Clinical Trial Supply Chain Management.
  • The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market.
  • It provides the idea of its revenue generation into the overall market compared to other vendors in the space.

Fresenius Kabi Introduces Generic Iodixanol Contrast Media Agent

Retrieved on: 
Monday, July 18, 2022
Medical Supplies, Biotechnology, Practice Management, FDA, Other Health, Health, General Health, Pharmaceutical, Medical Devices, Hospitals, Clinical Trials, Kidney, Skin, Agitation, Hospital, Lactation, Thyroid, Nervous, Heart, Iodixanol, Multimedia, Major trauma, Diagnosis, U.S. FDA, Blood, Sensation, Adult, CEO, Investment, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cardiac arrest, Food, Anxiety, Brain, Medication, Incidence, Life, Breast milk, Taste, Vomiting, Headache, Google Images, Death, Geriatrics, Patient, Hypersensitivity, Nervous system, LLC, Dizziness, Smell, USP, COVID-19, Shock, Pain, Risk, CT, Nausea, Migraine, Syncope, The New York Times, Diarrhea, Radiology, Pediatrics, Fresenius (company), GE Healthcare, Iodine, Insomnia, Pharmaceutical marketing, FDA, Pharmaceutical industry, Medical imaging, Salt, Dietary supplement, Foodservice, Cancer

View the full release here: https://www.businesswire.com/news/home/20220718005543/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220718005543/en/
    Fresenius Kabi Iodixanol Injection, USP is the first FDA-approved generic that is fully substitutable for Visipaque (Photo: Business Wire)
    Iodixanol Injection, USP is the first U.S. FDA-approved generic iso-osmolar, dimeric iodinated contrast media agent, which is used during diagnostic x-ray-based imaging such as computed tomography (CT) scans.
  • Iodixanol and other contrast media agents are in shortage across the U.S. due to COVID-19 related supply-chain disruptions.
  • Fresenius Kabi is pleased to help expand access to affordable, high-quality contrast media agents for the radiology community, said John Ducker, president and CEO of Fresenius Kabi USA.
  • The approval and U.S. availability of Fresenius Kabi Iodixanol Injection, USP is expected to provide immediate relief to the current shortage.

Insights on the Clinical Trial Supply & Logistics for Pharmaceutical US Market to 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 17, 2022
Pharmaceutical, Health, Clinical Trials, Certification, Use, Pharmaceutical marketing, Strategic management, R, Market share analysis, Decision-making, Value, Acquisition, Growth, Investment, COVID-19, Customer support, Business Growth Fund, Retail, Fine chemical, Pharmaceutical industry, Generic drug

What is the market size and forecast of the United States Clinical Trial Supply & Logistics for Pharmaceutical Market?

Key Points: 
  • What is the market size and forecast of the United States Clinical Trial Supply & Logistics for Pharmaceutical Market?
  • What is the competitive strategic window for opportunities in the United States Clinical Trial Supply & Logistics for Pharmaceutical Market?
  • What is the market share of the leading vendors in the United States Clinical Trial Supply & Logistics for Pharmaceutical Market?
  • What modes and strategic moves are considered suitable for entering the United States Clinical Trial Supply & Logistics for Pharmaceutical Market?